NASDAQ / LIVE COMPANY INTELLIGENCE

MiNK Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERINKT
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / INKT COVERAGE

What’s moving MiNK Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

Investors are testing whether MiNK Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript

Investors are testing whether MiNK Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th

MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th

The story matters when it changes MiNK Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript

Investors are testing whether MiNK Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
MiNK Therapeutics, Inc. (INKT) Q3 2023 Earnings Call Transcript

MiNK Therapeutics, Inc. (INKT) Q3 2023 Earnings Call Transcript

Investors are testing whether MiNK Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

The story matters when it changes MiNK Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest INKT filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-15 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-31 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-23 · Period 2026-06-17SEC ↗8-KMaterial company eventFiled 2026-05-15 · Period 2026-05-15SEC ↗8-KMaterial company eventFiled 2026-03-31 · Period 2026-03-31SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2026-06-17SEC ↗4Official SEC filingFiled 2026-06-05 · Period 2026-06-04SEC ↗
EARNINGS / QUARTERLY TRACKER

MiNK Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.